Isoray and its newly merged partner Viewpoint Molecular Targeting announced that they are now doing business as Perspective Therapeutics along with a new brand identity effective immediately. Isoray will change its name to Perspective Therapeutics by filing an amendment to its Certificate of Incorporation as soon as possible. Post-merger rebranding highlights include a new tagline: "Treating cancers from the inside out"; and website. New NYSE American stock ticker symbol to be CATX, effective February 21. Oppenheimer & Co. acted as Isoray’s financial advisor for the merger transaction and Gallagher & Kennedy served as Isoray’s legal counsel. Sichenzia Ross Ference acted as Viewpoint’s legal counsel.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISR:
- Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
- IsoRay announces results of 2023 Annual Meeting of Stockholders
- Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders
- Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023
- AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023
